002038:SZSEBeijing SL Pharmaceutical Co., Ltd. Analysis

The stock is trading at CNY 6.02, well under the 20‑day SMA of 6.50, the 50‑day SMA of 6.82 and the 200‑day SMA of 7.36, signalling a clear bearish price trend. RSI sits at 37, hinting at modest oversold pressure, while the MACD line remains below its signal line, reinforcing bearish momentum. Volume has been on a downtrend, and the price is hovering just above the identified support of 5.97 with resistance near 7.49.
Fundamentally, revenue contracted by 19% and the company posted a negative profit margin, yet gross margins stay robust at 63% and operating cash flow is healthy. The balance sheet is extremely strong – over CNY 1.1 billion in cash, zero debt and a PB ratio of 1.27. A DCF model values the shares around CNY 13, indicating the market is pricing the stock at roughly half of its intrinsic worth, and the modest 0.33% dividend appears sustainable given the cash cushion.
Risk is mixed: 30‑day volatility exceeds 50% and the max drawdown is 36%, but beta is near zero, limiting market‑wide swings. Sector risk is moderate, regulatory risk is medium due to drug approval cycles, geographic risk is medium given China‑centric operations, currency risk is low and liquidity risk is medium as volume trends downward despite a sizable market cap. Short‑term outlook suggests caution, while medium‑ to long‑term horizons present upside potential if profitability improves.